Molecular moulds with multiple missions: Functional sites in three-finger toxins

Clinical and Experimental Pharmacology and Physiology

Volumn 29, Issue 9, 2002, Pages 815-822

  Kini, R Manjunatha ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calciseptine; Cardiotoxin; Cytotoxin; Fasciculin; Functional site; Muscarinic toxin; Post synaptic neurotoxin; Protein protein interaction; Snake venom; Toxin evolution

Indexed keywords

ANTITHROMBOCYTIC AGENT; CALCISEPTINE; CALCIUM CHANNEL BLOCKING AGENT; CARDIOTOXIN; CHOLINESTERASE INHIBITOR; FASCICULIN; HANNALGESIN; NEUROTOXIN; SNAKE VENOM; UNCLASSIFIED DRUG;

ARTICLE; MOLECULAR BIOLOGY; MOULD; NONHUMAN; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

ANIMALS; ASIA; AUSTRALIA; HUMANS; MODELS, MOLECULAR; NEUROTOXINS; SNAKE VENOMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036381024     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2002.03725.x     Document Type: Article

References (63)

1. Lee CY. Snake Venoms. Handbook of Experimental Pharmacology, Vol. 52. Springer-Verlag, Berlin. 1979.
2. Harvey AL. Snake Toxins. Pergamon Press, New York. 1991.
3. Bailey GS. Enzymes from Snake Venom. Alaken, Fort Collins. 1998.
4. Tu AT. Reptile Venoms and Toxins. Marcel Decker, New York. 1991.
5. 2 Enzymes: Structure, Function and Mechanism. John Wiley and Sons, Chichester. 1997.
6. Dufton MT, Hider RC. Structure and pharmacology of elapid cytotoxins. Pharmacol. Ther. 1988; 36: 1-40.
7. Menez A. Functional architectures of animal toxins: A clue to drug design? Toxicon 1998; 36: 1557-72.
8. Tsetlin V. Snake venom alpha-neurotoxins and other 'three-finger' proteins. Eur. J. Biochem. 1999; 264: 281-6.
9. Changeux JP. The TiPS Lecture. The nicotinic acetylcholine receptor. An allosteric protein prototype of ligand-gated ion channels. Trends Pharmacol. Sci. 1990; 11: 485-92.
10. Grant GA, Chiappinelli VA. κ-Bungarotoxin: Complete amino acid sequence of a neuronal nicotinic receptor probe. Biochemistry 1985; 24: 1532-7.
11. Jerusalinsky D, Harvey AL. Toxins from mamba venoms: Small proteins with selectivities for different subtypes of muscarinic acetylcholine receptors. Trends Pharmacol. Sci. 1994; 15: 424-30.
12. De Weille JR, Schweitz H, Maes P, Tartar A, Lazdunski M. Calciseptine, a peptide isolated from black mamba venom, is a specific blocker of the L-type calcium channel. Proc. Natl Acad. Sci. USA 1991; 88: 2437-40.
13. Albrand JP, Blackledge MJ, Pascaud F, Hollecker M, Marion D. NMR and restrained molecular dynamics study of the three-dimensional solution structure of toxin FS2, a specific blocker of the L-type calcium channel, isolated from black mamba venom. Biochemistry 1995; 34: 5923-37.
14. Bilwes A, Rees B, Moras D, Menez R, Menez A. X-Ray structure at 1.55 A of toxin gamma, a cardiotoxin from Naja nigricollis venom. Crystal packing reveals a model for insertion into membranes. J. Mol. Biol. 1994; 239: 122-36.
15. McDowell RS, Dennis MS, Louie A, Shuster M, Mulkerrin MG, Lazarus RA. Mambin, a potent glycoprotein IIb-IIIa antagonist and platelet aggregation inhibitor structurally related to the short neurotoxins. Biochemistry 1992; 31: 4766-72.
16. Fleming TJ, O'hUigin C, Malek TR. Characterization of two novel Ly-6 genes. Protein sequence and potential structural similarity to alpha-bungarotoxin and other neurotoxins. J. Immunol. 1993; 150: 5379-90.
17. Ploug M, Ellis V. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett. 1994; 349: 163-8.
18. Gumley TP, McKenzie IFC, Sandrin MS. Tissue expression, structure and function of the murine Ly-6 family of molecules. Immunol. Cell Biol. 1995; 73: 277-96.
19. Miwa JM, Ibanez-Tallon I, Crabtree GW et al. lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine receptors in the mammalian CNS. Neuron 1999; 23: 105-14.
20. Cordero-Erausquin M, Marubio LM, Klink R, Changeux JP. Nicotinic receptor function: New perspectives from knockout mice. Trends Pharmacol. Sci. 2000; 21: 211-17.
21. Unwin N. Nicotinic acetylcholine receptor at 9 Å resolution. J. Mol. Biol. 1993; 229: 1101-24.
22. Servent D, Winckler-Dietrich V, Hu HY et al. Only snake curaremimetic toxins with a fifth disulfide bond have high affinity for the neuronal alpha7 nicotinic receptor. J. Biol. Chem. 1997; 272: 24 279-86.
23. Servent D, Antil-Delbeke S, Corringer PJ, Changeux JP, Ménez A. Molecular characterization of the specificity of interactions of various neurotoxins on two distinct nicotinic acetylcholine receptors. Eur. J. Pharmacol. 2000; 393: 197-204.
24. Antil-Delbeke S, Gaillard C, Tamiya T et al. Molecular determinants by which a long chain toxin from snake venom interacts with the neuronal alpha 7-nicotinic acetylcholine receptor. J. Biol. Chem. 2000; 275: 29 594-601.
25. Karlsson E, Jolkkonen M, Mulugeta E, Onali P, Adem A. Snake toxins with high selectivity for subtypes of muscarinic acetylcholine receptors. Biochimie 2000; 82: 793-806.
26. Carlsson FHH. Snake venom toxins. The primary structure of protein S4C11. A neurotoxin homologue from the venom of forest cobra (Naja melanoleuca). Biochim. Biophys. Acta 1975; 400: 310-21.
27. Joubert FJ. The purification and amino acid sequence of toxin CM-13b from Naja haje annulifera (Egyptian cobra) venom. Hoppe-Seylers Z. Physiol. Chem. 1975; 356: 1901-8.
28. Joubert FJ, Taljaard N. Snake venoms. The amino acid sequences of two Melanoleuca-type toxins. Hoppe-Seylers Z. Physiol. Chem. 1980; 361: 425-36.
29. Utkin YN, Kukhtina VV, Maslennikov IV et al. First tryptophan-containing weak neurotoxin from cobra venom. Toxicon 2001; 39: 921-7.
30. Utkin YN, Kukhtina VV, Kryukova EV et al. 'Weak toxin' from Naja kaouthia is a nontoxic antagonist of alpha 7 and muscle-type nicotinic acetylcholine receptors. J. Biol. Chem. 2001; 276: 15 810-15.
31. Nirthanan S, Charpantier E, Gopalakrishnakone P et al. Candoxin, a novel toxin from Bungarus candidus is a reversible antagonist of muscle (αβγδ) but a poorly reversible antagonist of neuronal 7 nicotinic acetylcholine receptors. J. Biol. Chem. 2002; 277: 17 811-20.
32. Eastman J, Wilson EJ, Cervanansky C, Rosenberry TL. Fasciculin 2 binds to the peripheral site on acetylcholinesterase and inhibits substrate hydrolysis by slowing a step involving proton transfer during enzyme acylation. J. Biol. Chem. 1995; 270: 19 694-701.
33. Condrea E. Hemolytic disorders associated with a primary red cell membrane defect. Experentia 1975; 32: 537-42.
34. Takechi M, Tanaka Y, Hayashi K. Amino acid sequence of a cardiotoxin-like basic polypeptide (CLBP) with low cytotoxic activity isolated from the venom of the Formosan cobra (Naja naja atra). Biochem. Int. 1985; 11: 795-802.
35. Sivaraman T, Kumar TK, Yang PW, Yu C. Cardiotoxin-like basic protein (CLBP) from Naja naja atra is not a cardiotoxin. Toxicon 1997; 35: 1367-71.
36. Yasuda O, Morimoto S, Chen Y et al. Calciseptine binding to a 1,4-dihydropyridine recognition site of the L-type calcium channel of rat synaptosomal membranes. Biochem. Biophys. Res. Commun. 1993; 194: 587-94.
37. Pillet L, Tremeau O, Ducancel F et al. Genetic engineering of snake toxins. Role of invariant residues in the structural and functional properties of a curaremimetic toxin, as probed by site-directed mutagenesis. J. Biol. Chem. 1993; 268: 909-16.
38. Tremeau O, Lemaire C, Drevet P et al. Genetic engineering of snake toxins. The functional site of Erabutoxin a, as delineated by site-directed mutagenesis, includes variant residues. J. Biol. Chem. 1995; 270: 9362-9.
39. Antil S, Servent D, Ménez A. Variability among the sites by which curaremimetic toxins bind to torpedo acetylcholine receptor, as revealed by identification of the functional residues of α-cobratoxin. J. Biol. Chem. 1999; 274: 34 851-8.
40. Kini RM, Evans HJ. A common cytolytic region in myotoxins, hemolysins, cardiotoxins and antibacterial peptides. Int. J. Peptide Protein Res. 1989; 34: 277-86.
41. Kini RM, Evans HJ. Role of cationic amino acid residues in cytolytic activity. Modifications of lysine residues in the cardiotoxin from Naja nigricollis venom and correlation between cytolytic and antiplatelet activities. Biochemistry 1989; 28: 9209-15.
42. Kini RM, Iwanaga S. Structure-function relationships of phospholipases I. Prediction of presynaptic neurotoxicity. Toxicon 1986; 24: 527-41.
43. Kini RM, Iwanaga S. Structure-function relationships of phospholipases II. Charge density distribution and the myotoxicity of presynaptically neurotoxic phospholipases. Toxicon 1986; 24: 895-905.
44. Gatineau E, Takechi M, Bouet F et al. Delineation of the functional site of a snake venom cardiotoxin: Preparation, structure, and function of monoacetylated derivatives. Biochemistry 1990; 29: 6480-9.
45. Carlsson FHH, Louw AI. The oxidation of methionine and its effect of the properties of cardiotoxin V 1 II from Naja melanoleuca venom. Biochim. Biophys. Acta 1978; 534: 322-30.
46. Dauplais M, Neumann JM, Pinkasfeld S, Ménez A, Roumestand C. An NMR study of the interaction of cardiotoxin γ from Naja nigricollis with perdeuterated dodecylphosphocholine micelles. Eur. J. Biochem. 1995; 230: 213-20.
47. Falkenstein RJ, Pena C. Synthetic peptides derived from the central loop of fasciculin: Structural analysis and evaluation as acetylcholinesterase inhibitors. Biochim. Biophys. Acta 1997; 1340: 143-51.
48. Marchot P, Prowse CN, Kanter J et al. Expression and activity of mutants of fasciculin, a peptidic acetylcholinesterase inhibitor from mamba venom. J. Biol. Chem. 1997; 272: 3502-10.
49. Karlsson E, Mbugua PM, Rodriguez-Ithurralde D. Fasciculins, anticholinesterase toxins from the venom of the green mamba Dendroaspis angusticeps. J. Physiol. 1984; 79: 232-40.
50. Ricciardi A, Le Du MH, Khayati M et al. Do structural deviations between toxins adopting the same fold reflect functional differences? J. Biol. Chem. 2000; 275: 18 302-10.
51. Kini RM, Evans HJ. A common structural feature enclosing interaction sites: Prediction of protein-protein interaction sites and development of potent bioactive peptides. In: Menon J (ed.). Current Topics in Peptide and Protein Research, Vol. 1. Council of Scientific Information, Trivandrum. 1994; 297-311.
52. Kini RM, Evans HJ. A hypothetical structural role for proline residues in the flanking segments of protein-protein interaction sites. Biochem. Biophys. Res. Commun. 1995; 212: 1115-24.
53. Kini RM. Proline brackets and identification of potential functional sites in proteins: Toxins to therapeutics. Toxicon 1998; 36: 1659-70.
54. Kini RM, Evans HJ. Prediction of potential protein-protein interaction sites from amino acid sequence. Identification of a fibrin polymerization site. FEBS Lett. 1996; 385: 81-6.
55. 2+ channel binding site of calciseptine and FS2. Biochemistry 1998; 37: 9058-63.
56. Schleifer KJ. Comparative molecular modelling study of the calcium channel blockers nifedipine and black mamba toxin FS2. J. Comput. Aided Mol. Des. 1997; 11: 491-501.
57. Lu X, Sun Y, Shang D et al. Evaluation of the role of proline residues flanking the RGD motif of dendroaspin, an inhibitor of platelet aggregation and cell adhesion. Biochem. J. 2001; 355: 633-8.
58. 3 integrins. Biochem. J. 2001; 356: 11-17.
59. Pu XC, Wong PT, Gopalakrishnakone P. A novel analgesic toxin (Hannalgesin) from the venom of king cobra (Ophiophagus hannah). Toxicon 1995; 33: 1425-31.
60. Gopalakrishnakone P, Wong P, Gwee MCE, Kini RM, inventors. National University of Singapore, assignee. Therapeutic molecules. Singapore patent pending. 20 September 1996.
61. 2 isozyme genes. Proc. Natl Acad. Sci. USA 1995; 92: 5605-9.
62. Deshimaru M, Ogawa T, Nakashima K et al. Accelerated evolution of crotalinae snake venom gland serine proteases. FEBS Lett. 1996; 397: 83-8.
63. Ohno M, Ménez R, Ogawa T et al. Molecular evolution of snake toxins: Is the functional diversity of snake toxins associated with a mechanism of accelerated evolution? Prog. Nucleic Acids Res. Mol. Biol. 1998; 59: 307-64.